Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.

Alapafuja SO, Nikas SP, Bharathan IT, Shukla VG, Nasr ML, Bowman AL, Zvonok N, Li J, Shi X, Engen JR, Makriyannis A.

J Med Chem. 2012 Nov 26;55(22):10074-89. doi: 10.1021/jm301205j. Epub 2012 Nov 2.

2.

Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.

Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, Osei-Hyiaman D, Liu J, Mukhopadhyay B, Harvey-White J, Tam J, Pacak K, Blankman JL, Cravatt BF, Makriyannis A, Kunos G.

Chem Biol. 2010 Nov 24;17(11):1256-66. doi: 10.1016/j.chembiol.2010.08.013.

3.

Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.

Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, Omeir RL, Makriyannis A.

Biochem Biophys Res Commun. 1997 Feb 3;231(1):217-21.

PMID:
9070252
4.

Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.

Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M.

Anesth Analg. 2009 Jan;108(1):316-29. doi: 10.1213/ane.0b013e31818c7cbd.

PMID:
19095868
5.

Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, Makriyannis A, Poulton R, Patel S, Hariri AR, Caspi A, Moffitt TE, Kunos G, Holmes A.

Mol Psychiatry. 2013 Jul;18(7):813-23. doi: 10.1038/mp.2012.72. Epub 2012 Jun 12.

6.

Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.

Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, Makriyannis A, Davison JS, Sharkey KA.

Br J Pharmacol. 2012 Mar;165(5):1556-71. doi: 10.1111/j.1476-5381.2011.01644.x.

8.

Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).

Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H, Lindstrom M, Xu G, Uyeda C, Ma Z, Li Y, Kayser F, Walker NP, Wang Z.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7379-84. doi: 10.1073/pnas.1016167108. Epub 2011 Apr 18.

9.

Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.

Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2492-6. doi: 10.1016/j.bmcl.2011.02.052. Epub 2011 Feb 17.

PMID:
21392988
10.

Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.

Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, Surowy C, El Kouhen OF, Muchmore SW, Brioni JD, Stewart AO.

J Med Chem. 2009 Jan 8;52(1):170-80. doi: 10.1021/jm801042a.

PMID:
19072118
11.

A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison.

Labar G, Vliet FV, Wouters J, Lambert DM.

Amino Acids. 2008 Jan;34(1):127-33. Epub 2007 May 4.

PMID:
17476568
12.

Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency.

Tian G, Paschetto KA, Gharahdaghi F, Gordon E, Wilkins DE, Luo X, Scott CW.

Biochemistry. 2011 Aug 16;50(32):6867-78. doi: 10.1021/bi200552p. Epub 2011 Jul 22.

PMID:
21728345
13.

Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):407-23. Epub 2006 May 31.

PMID:
16736384
14.

Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode.

Karlsson J, Morgillo CM, Deplano A, Smaldone G, Pedone E, Luque FJ, Svensson M, Novellino E, Congiu C, Onnis V, Catalanotti B, Fowler CJ.

PLoS One. 2015 Nov 13;10(11):e0142711. doi: 10.1371/journal.pone.0142711. eCollection 2015.

15.

Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage.

Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA.

J Pharmacol Exp Ther. 2007 Sep;322(3):1059-66. Epub 2007 Jun 1.

16.

Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA.

J Neurosci. 2005 Aug 24;25(34):7813-20.

17.

Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).

Korhonen J, Kuusisto A, van Bruchem J, Patel JZ, Laitinen T, Navia-Paldanius D, Laitinen JT, Savinainen JR, Parkkari T, Nevalainen TJ.

Bioorg Med Chem. 2014 Dec 1;22(23):6694-705. doi: 10.1016/j.bmc.2014.09.012. Epub 2014 Sep 16.

PMID:
25282655
18.

N-(3,4-Dimethylisoxazol-5-yl)piperazine-4-[4-(2-fluoro-4-[(11)C]methylphenyl)thiazol-2-yl]-1-carboxamide: A promising positron emission tomography ligand for fatty acid amide hydrolase.

Shimoda Y, Fujinaga M, Hatori A, Yui J, Zhang Y, Nengaki N, Kurihara Y, Yamasaki T, Xie L, Kumata K, Ishii H, Zhang MR.

Bioorg Med Chem. 2016 Feb 15;24(4):627-34. doi: 10.1016/j.bmc.2015.12.026. Epub 2015 Dec 15.

PMID:
26740152
19.

Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.

Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CR, Jorgensen WL, Cravatt BF.

J Med Chem. 2005 Mar 24;48(6):1849-56.

20.

Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen.

Cipriano M, Björklund E, Wilson AA, Congiu C, Onnis V, Fowler CJ.

Eur J Pharmacol. 2013 Nov 15;720(1-3):383-90. doi: 10.1016/j.ejphar.2013.09.065. Epub 2013 Oct 8.

PMID:
24120370

Supplemental Content

Support Center